Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience.

被引：3
|
作者：
Lau, Sally C. M.
Perdrizet, Kirstin
Mata, Danilo Giffoni de Mello Morais
Fung, Andrea S.
Liu, Geoffrey
Bradbury, Penelope Ann
Shepherd, Frances A.
Sacher, Adrian G.
Sheffield, Brandon
Hwang, David
Tsao, Ming Sound
Cheng, Susanna Y.
Cheema, Parneet
Leighl, Natasha B.
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[4] Canc Ctr Southeastern Ontario, Kingston, ON, Canada
[5] Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[7] William Osler Hlth Ctr, Brampton, ON, Canada
[8] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada
[9] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[10] Univ Toronto, William Osler Hlth Syst, Toronto, ON, Canada
[11] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21123
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
    Veillon, Remi
    Sakai, Hiroshi
    Le, Xiuning
    Felip, Enriqueta
    Cortot, Alexis B.
    Smit, Egbert F.
    Park, Keunchil
    Griesinger, Frank
    Britschgi, Christian
    Wu, Yi-Long
    Melosky, Barbara
    Baijal, Shobhit
    de Castro Jr, Gilberto
    Sedova, Michaela
    Berghoff, Karin
    Otto, Gordon
    Paik, Paul K.
    CLINICAL LUNG CANCER, 2022, 23 (04) : 320 - 332
  • [32] Circulating Tumor DNA Analysis in NSCLC with MET exon 14 Skipping Alterations
    Le, X.
    Hong, L.
    Kemp, H.
    Saam, J.
    Hensel, C.
    Raymond, V.
    Zhang, J.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S207 - S208
  • [33] Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib
    Kauffmann-Guerrero, Diego
    Kahnert, Kathrin
    Kumbrink, Joerg
    Syunyaeva, Zulfiya
    Tufman, Amanda
    Huber, Rudolf M.
    CLINICAL LUNG CANCER, 2019, 20 (01) : 59 - 62
  • [34] Clinical Background and Response to Chemotherapy in NSCLC Patients with MET Exon14 Skipping Mutation or High MET Gene Copy Number
    Nosaki, K.
    Umeyama, Y.
    Toyozawa, R.
    Takamori, S.
    Haratake, N.
    Miura, N.
    Oba, T.
    Yamaguchi, M.
    Seto, T.
    Takenoyama, M.
    Ichinose, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S896 - S896
  • [35] Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC
    Garassino, Marina C.
    Le, Xiuning
    Iam, Wade T.
    Felip, Enriqueta
    Sakai, Hiroshi
    Veillon, Remi
    Smit, Egbert F.
    Mazieres, Julien
    Raskin, Jo
    Cortot, Alexis B.
    Berghoff, Karin
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul K.
    CANCER RESEARCH, 2022, 82 (12)
  • [36] Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
    Kim, So Yeon
    Yin, Jun
    Bohlman, Stephen
    Walker, Phillip
    Dacic, Sanja
    Kim, Chul
    Khan, Hina
    Liu, Stephen V.
    Ma, Patrick C.
    Nagasaka, Misako
    Reckamp, Karen L.
    Abraham, Jim
    Uprety, Dipesh
    Wang, Feng
    Xiu, Joanne
    Zhang, Jian
    Cheng, Haiying
    Halmos, Balazs
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (09):
  • [37] Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors
    Duarte, F. A.
    Dienstmann, R.
    Diniz, P. H. C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S424 - S425
  • [38] MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression
    Gimenez-Capitan, Ana
    Teixido, Cristina
    Aguado, Cristina
    Rodriguez, Sonia
    Bertran-Alamillo, Jordi
    Castellvi, Josep
    Yeste, Zaira
    Perez, Ana
    Rosell, Rafael
    Molina-Vila, Miguel Angel
    CANCER RESEARCH, 2017, 77
  • [39] MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History
    Marks, J.
    Yin, J.
    Halmos, B.
    Bazhenova, L.
    Ramalingam, S. S.
    Marmarelis, M. E.
    Xiu, J.
    Walker, P.
    Oberley, M.
    Ma, P. C.
    Liu, S. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S61 - S61
  • [40] Lung adenocarcinoma with MET exon 14 skipping mutation; clinicopathological characteristics and immunohistochemical MET expression
    Motoi, Noriko
    Sunami, Kuniko
    Ohe, Yuichiro
    Watanabe, Shun-ichi
    Kohno, Takashi
    LABORATORY INVESTIGATION, 2018, 98 : 742 - 742
12345